Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.

@article{Pnisch2013LenalidomideBA,
  title={Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.},
  author={Wolfram P{\"o}nisch and Simone Heyn and Juliane Beck and Ina Wagner and Martin Mohren and Franz Albert Hoffmann and Thoralf Lange and Marion Schmalfeld and Thomas Zehrfeld and Andreas Schwarzer and Cornelia Winkelmann and Thomas A. Edelmann and Ramona R{\"o}hrborn and Karin Hebenstreit and Haifa Kathrin Al-Ali and Nadja Jaekel and Dietger Niederwieser},
  journal={British journal of haematology},
  year={2013},
  volume={162 2},
  pages={202-9}
}
This phase 1 dose finding study tested a combination of lenalidomide, bendamustine and prednisolone (RBP) in 21 patients in five cohorts with advanced multiple relasped/refractory myeloma (MM) to determine the maximum tolerable dose (MTD) of the combination. The first cohort received a starting dose of lenalidomide 10 mg/d, days 1-21, bendamustine 60 mg/m(2) /d, days 1-2, and prednisolone 100 mg/d, days 1-4. Dose escalation was done in cohorts of three to six patients with lenalidomide dose… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
14 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…